Clinical trial
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
NCT00044863 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00044863 |
|---|---|
| Title | Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma |
| Official title | A Phase II Multicenter Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms, Metastases, Neoplasm |
| Intervention type | Biological |
| Interventions | Erbitux (Cetuximab) |
| Enrollment | 250 |
| Start date | Aug 1, 2002 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 9, 2002 |
| Last update posted | Feb 23, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: